13 August 2024 : Original article
Kidney After Lung Transplants or Combined Kidney–Lung Transplantation: A Single-Center Retrospective Cohort Study
Benoît Mesnard1ABCDEF*, Matthieu Glorion
2ABCDF, Arwa Jalal Eddine3ABCE, Antoine Roux4ABF, Julien Branchereau5ADE, Yann Neuzillet1CDE, Edouard Sage2BDF, Thierry Lebret1CEF, Alexandre Hertig3ABDEF, François-Xavier Madec1ABCDE, Yanish Soorojebally1ABCDEFG
DOI: 10.12659/AOT.944049
Ann Transplant 2024; 29:e944049
Table 1 Recipient characteristics.
| Global populationN=26 | Combined lung kidney transplantationN=17 (65.38%) | Kidney after lung transplantationN=9 (34.62%) | Odds ratio, (95% CI), p | |
|---|---|---|---|---|
| Sex ratio | 0.73 | 0.89 | 0.5 | 0.500 |
| Age at transplantation | 36.5 (16) | 35 (9) | 45 (14) | 0.107 |
| Weight (kg) | 53.5 (19) | 51 (24) | 59 (11) | 0.874 |
| Height (cm) | 169.5 (14) | 170 (12) | 163 (12) | 0.525 |
| BMI | 18.88 (3.3) | 18.73 (3.7) | 19.69 (2.73) | 0.220 |
| Diabetes | 17 (65.39%) | 13 (76.47%) | 4 (44.44%) | 0.102 |
| Hypertension | 11 (42.31%) | 7 (41.18%) | 4 (44.44%) | 0.873 |
| Neoplasia | 3 (11.54%) | 1 (5.88%) | 2 (22.22%) | 0.215 |
| Platelet antiaggregant | 1 (3.85%) | 1 (5.88%) | 0 | 0.458 |
| Anticoagulant | 3 (11.54%) | 1 (5.88%) | 2 (22.22%) | 0.215 |
| Positive CMV status | 14 (58.33%) | 8 (50%) | 6 (75%) | 0.242 |
| Previous transplant | 19 (73.08%)Lung: 16 (84.21%)Lung then kidney: 1 (5.26%)Liver: 1 (5.26%)Marrow allotransplantation: 1 (5.26%) | 10 (58.82%)Lung: 8 (80%)Liver: 1 (10%)Marrow allotransplantation: 1 (10%) | 9 (100%)Lung: 8 (88.89%)Lung then kidney: 1 (11.11%) | 0.024 |
| Time between lung and kidney transplantation (years) | 10 (5) | |||
| Etiology of renal failure | Anticalcineurin toxicity: 17 (65.39%)Chronic glomerulonephritis: 3 (11.54%)Diabetic nephropathy: 3 (11.54%)Autosomal-dominant polycystickidney disease: 1 (3.85%)Renal amyloidosis: 1 (3.85%)Cruoric embolism after lung transplantation: 1 (3.85%) | Anticalcineurin toxicity: 9 (52.94%)Chronic glomerulonephritis: 3 (17.65%)Diabetic nephropathy: 3 (17.65%)Autosomal-dominant polycystickidney disease: 1 (5.88%)Renal amyloidosis: 1 (5.88%) | Anticalcineurin toxicity: 8 (88.89%)Cruoric embolism after lung transplantation: 1 (11.11%) | 0.200 |
| Necessity of dialysis introduction | 9 (34.62%)Haemodialysis: 8 (88.89%)Peritoneal dialysis: 1 (11.11%) | 2 (11.77%)Haemodialysis: 2 (100%) | 7 (77.78%)Haemodialysis: 6 (85.71%)Peritoneal dialysis: 1 (14.29%) | <0.001 |
| Dialysis duration | 7 (19) | 15 (18) | 7 (18) | 0.854 |
| Etiology of respiratory failure | Cystic fibrosis: 21 (80.77%)Emphysema: 1 (3.85%)Bronchiectasis: 1 (3.85%)Graft versus Host: 1 (3.85%)Mac leod syndrome: 1 (3.85%)Pulmonary fibroelastosis: 1 (3.85%) | Cystic fibrosis: 14 (82.35%)Graft versus Host: 1 (5.88%)Mac leod syndrome: 1 (5.88%)Pulmonary fibroelastosis: 1 (5.88%) | Cystic fibrosis: 7 (77.78%)Emphysema: 1 (11.11%)Bronchiectasis: 1 (11.11%) | 0.371 |
| Percentage of second lung transplants in each etiology | Cystic fibrosis: 50% (7) Graft versus Host: 0%Mac leod syndrome: 100% (1) Pulmonary fibroelastosis: 0% | |||
| Preoperative extracorporeal membrane oxygenation | 2 (11.77%) | |||
| Continuous variables were expressed as median and interquartile range (IQR) and categorical variables were expressed as n and percentages. | ||||